Disclaimer: The views expressed in this contributed article are those of the author and do not necessarily reflect the views of CannabisTech.com. This content is for informational purposes only and does not constitute legal, tax, or investment advice.
Table of Contents
Article by Jon Lowen, co‑CEO of Surfside
This month’s Schedule III action is a margin story before it is a marketing story. The Department of Justice is moving FDA-approved marijuana products and medical cannabis products regulated under qualifying state licenses into Schedule III, and it has opened a hearing process on June 29, 2026 to consider broader rescheduling. That should not be mistaken for full federal legalization.
It also does not remove the structural regulatory constraints that shape cannabis advertising. What it may do however, for the narrow set of operators covered, is ease the tax pressure that has been distorting how cannabis companies evaluate every dollar of growth investment.
Why 280E raised the bar on every campaign
For years, cannabis operators have underwritten marketing through a punishing lens. Section 280E makes ordinary business expenses, including payroll, rent, technology, legal fees, and marketing, effectively non-deductible at the federal level. That compresses margins in a way that raises the hurdle rate on every campaign.
Marketing had to clear a structurally higher bar than the same campaign would face in any other consumer category. Reuters reported that the most consequential business effect of the current rescheduling action is potential relief from 280E for the covered medical segment.
What actually changes
This does not mean cannabis companies should suddenly spend more. Rather, the practical implication is that the same marketing performance may be judged differently under a less distorted margin structure. Campaigns that were already working should become more profitable, and programs that looked marginal under a punitive tax framework may look reasonable under a more normalized one. The evaluation question shifts from “Did this clear an artificially high post-tax hurdle?” to “What contribution did this actually create for the business?”
There is also a budgeting implication worth naming. Under heavy tax pressure, operators tend to concentrate spend in the most transactional, fastest-payback media. When margins are compressed, patience for upper-funnel work is short. If tax treatment normalizes, businesses gain the flexibility to evaluate a healthier mix across awareness, consideration, retention, and loyalty. That is an argument for a wider aperture within disciplined evaluation. In cannabis, where consumer choice remains fragmented and brand differentiation is still maturing, repeated exposure across channels can meaningfully influence the final basket decision.
Whitney Economics recently estimated that legal cannabis operators paid roughly $2.24 billion in excess federal taxes in 2025 because of 280E, with marketing among the ordinary business expenses caught in that burden. Relief will not arrive evenly or immediately given the narrow scope of the current action, but the scale of the distortion underscores why tax treatment has had such an outsized effect on how cannabis businesses underwrite growth.
Where policy becomes operating leverage
The second-order effect is where this gets interesting for retail and commercial infrastructure. If dispensaries and cannabis retailers retain more cash flow, they are better positioned to invest in the systems that compound marketing value over time: first-party audience development, cleaner reporting, stronger onsite merchandising, more scalable retail media programs, and tighter closed-loop measurement. This is where policy change becomes operating leverage. The immediate benefit is margin relief. The strategic benefit is the ability to fund better growth systems rather than simply paying a heavier tax bill.
What this does not fix
Let’s be honest about what has not changed because the action is limited in scope. It does not federally legalize adult-use cannabis. It leaves banking, the broader federal-state conflict, and a number of structural constraints unresolved, which is why cannabis equities rallied on the announcement and then gave back gains as investors absorbed the narrower reality. The economics may improve for a subset of operators, but the regulatory environment remains intact.
The practical takeaway for cannabis marketers is straightforward: Schedule III may make the economics around marketing more rational for the businesses the action covers. That doesn’t necessarily make marketing easier, but the opportunity is to revisit assumptions, recalculate historical performance under a different tax lens, and reassess where profitability thresholds may shift if 280E pressure eases. Overall, there’s an opportunity to make better decisions on a less distorted financial foundation.
